William Patalon III- Money Morning - Only the News You Can Profit From.
William (Bill) Patalon III is the Executive Editor and Senior Research Analyst for Money Morning at Money Map Press. Before he moved into the investment-research business in December 2005, Bill spent 22 years as a journalist, most of it covering financial news as a reporter, columnist, and editor that included stints with Gannett Co. Inc., and The Baltimore Sun.
Bill has covered finance and investing, economics, manufacturing, the defense sector, biotechnology, and telecommunications. The companies he’s covered include Eastman Kodak, Xerox, Harley-Davidson, Caterpillar, Westinghouse Electric, Verizon, MedImmune, and Black & Decker.
His most-memorable interviews include: former President Richard M. Nixon, General Electric CEO John F. “Jack” Welch, Forbes magazine publisher and former Presidential candidate Steve Forbes, and business-turnaround specialist and helicopter-industry pioneer Stanley Hiller Jr.
It was Bill’s work covering Eastman Kodak Co., during the last half of the 1990s that solidified his reputation as one of the nation’s top analytical business journalists. With his award-winning reports on Kodak’s competitive travails, he consistently scooped his competitors in the national business media. His chronicles of Kodak’s turnaround efforts took him to China, Japan, Silicon Valley, New York, Washington, D.C., and even Hollywood.
His work has appeared in Kiplinger’s personal finance magazine, USA Today, and The South China Morning Post, among other publications. A winner of approximately two-dozen journalism awards – including top honors from The Associated Press and the prestigious Society of American Business Editors and Writers (SABEW). Patalon is also the co-author of the Prentice Hall book, "Contrarian Investing: How to Buy and Sell When Others Won’t and Make Money Doing It." Before taking over Money Morning, he served as the editor of The Rebound Report, an investment newsletter focusing on turnaround stocks.
Today Bill is the creator and editor of Private Briefing. With his latest project, he takes you "behind the scenes" of his established investment news website for a closer look at the action. Members get all the expert analysis and exclusive scoops he can't publish… and some of the most valuable picks that turn up in Bill's closed-door sessions with editors and experts.
Bill has a BA in Print Journalism from Penn State University, and an MBA in finance from the Rochester Institute of Technology.
William'S LATEST HEADLINES
- Biotech Stocks 0 Tuesday, August 11, 2020Profit on This Biotech-Enabler That's Suddenly a "Buy"
"Lead, follow, or get out of the way."
This is one of those well-known aphorisms that's been around forever – though its originator is unknown.
Truth be told, it doesn't matter who said it first. It's a great bit of advice.
Especially as we interpret it.
In our investment work here at Money Morning, we always seek to lead Wall Street and the rest of the packrat investment crowd.
We never follow, especially since "the crowd" tends to be indecisive, late to the gun – or flat out wrong.
And we always get out of the way – sidestepping the dust-rising thump that's an inevitable result of the miscues and sins of the Wall Street Goliath.
It's a simple formula. And a successful one.
And it's the reason we keep outperforming "the crowd."
Like the 2,067% gain on biotech Galapagos NV, the very first stock I recommended on the very first day I published my Member-based service, Private Briefing, back in August 2011.
My readers also pulled down peak gains of more than 2,892% in Nvidia, 2,828% in Advanced Micro Devices, 818% in biotech buyout Pharmacyclics, and more.
Today, I've decided to share my latest insight on one of my big biotech winners with Money Morning readers because the opportunity is too good to keep to ourselves. And since my colleague Michael Robinson recently talked about 2020's record-crushing biotech IPOs, it's the perfect time to share this.
The company I'm showing you today is essential to biotech stocks. It's a "biotech-enabler" that's zoomed 1,755% since I first told my readers about it back in June 2013.
In 2013, it was trading at $8.14.
It closed July 30 at $151.25 – not long after Investor's Business Daily said the stock had entered a "Buy Zone."
True, but where were they seven years and 1,755% ago?
Of course, what's important now is what comes next – and it's clear this stock's run isn't over… Full StoryOf course, what's important now is what comes next - and it's clear this stock's run isn't over...
- COVID-19 Stock Market Crash Monday, July 20, 2020This "Infection Correction" Stock Has More Than Doubled Since March – and It's Not Too Late to Get In
- Friday, June 19, 2020The Core Stocks to Own for Years to Come
- COVID-19 Stock Market Crash Tuesday, May 26, 2020The Fine Art of Defensive Investing in Today's "Disruption Economy"
- COVID-19 Stock Market Crash Tuesday, May 19, 2020How to Invest $2,000 Right Now
- COVID-19 Monday, May 11, 2020The "Zoom of Healthcare" May Be the Greatest Company You Haven't Heard Of
- COVID-19 Stock Market Crash Wednesday, May 6, 2020The "COVID-19 Trigger Effect" Means Cash Is Trash – and Makes This Payment Innovator a Stock You Have to Own
- Apple Wednesday, April 22, 2020Apple Stock Will Still Hit $400 per Share
- COVID-19 Stock Market CrashThese Cash-Rich Companies Give You a Safety Net Today – and Wealth for Years to Come
- COVID-19 Stock Market Crash Saturday, April 18, 2020A Double-Your-Money Tech Titan with Low Risk and Big Upside